brand logo

Am Fam Physician. 2019;99(1):49

Author disclosure: No relevant financial affiliations.

Clinical Question

Does antibiotic prophylaxis decrease mortality in hospitalized patients with severe acute pancreatitis?

Evidence-Based Answer

No, antibiotic prophylaxis does not decrease mortality in patients with severe acute pancreatitis, defined as pancreatitis associated with pancreatic necrosis. (Strength of Recommendation: A, based on meta-analyses of randomized controlled trials [RCTs] and a single RCT.)

Evidence Summary

A 2010 meta-analysis of seven RCTs (N = 404) evaluated the effect of antibiotic therapy vs. no antibiotics or placebo on rates of mortality and infected pancreatic necrosis in patients with computed tomography–confirmed severe acute pancreatitis.1 The mean age of participants ranged from 43 to 50 years, and most patients had pancreatitis secondary to alcohol use (50%) or biliary disease (24%). Antibiotics included β-lactams, quinolones plus imidazole, or imipenem/cilastatin (Primaxin IV), and were given for 14 to 21 days. Infected pancreatic necrosis was confirmed by culture of aspirate. Overall, antibiotic prophylaxis did not decrease mortality compared with placebo (relative risk [RR] = 0.60; 95% confidence interval [CI], 0.34 to 1.1). Imipenem/cilastatin did decrease rates of infected pancreatic necrosis (two studies; N = 160; RR = 0.34; 95% CI, 0.13 to 0.84), but β-lactams and quinolones plus imidazole did not. None of the studies was adequately powered, only two were double-blinded, and only four had appropriate allocation concealment.

Another meta-analysis included the seven RCTs from the 2010 meta-analysis plus an additional single-blind RCT (n = 35) of ciprofloxacin plus metronidazole (Flagyl), meropenem (Merrem IV), or placebo.2 This meta-analysis also showed no mortality benefit from antibiotic prophylaxis (N = 439; RR = 0.76; 95% CI, 0.49 to 1.2).

A 1996 double-blind RCT (n = 23) evaluated mortality in patients with severe acute pancreatitis secondary to alcohol use.3 Patients were randomized to a 10-day course of ceftazidime (Fortaz), 2 g every eight hours; amikacin, 7.5 mg per kg every 12 hours; or metronidazole, 500 mg every eight hours; or placebo. Patients were 21 to 71 years of age with pancreatic fluid collections noted on computed tomography. Three patients in the placebo group and one patient in the antibiotic group died (reported as not statistically significant, but no P value was given).

Copyright © Family Physicians Inquiries Network. Used with permission.

Help Desk Answers provides answers to questions submitted by practicing family physicians to the Family Physicians Inquiries Network (FPIN). Members of the network select questions based on their relevance to family medicine. Answers are drawn from an approved set of evidence-based resources and undergo peer review. The strength of recommendations and the level of evidence for individual studies are rated using criteria developed by the Evidence-Based Medicine Working Group (https://www.cebm.net).

The complete database of evidence-based questions and answers is copyrighted by FPIN. If interested in submitting questions or writing answers for this series, go to https://www.fpin.org or email:  questions@ fpin.org.

This series is coordinated by John E. Delzell Jr., MD, MSPH, associate medical editor.

A collection of FPIN’s Help Desk Answers published in AFP is available at https://www.aafp.org/afp/hda.

Continue Reading


More in AFP

More in Pubmed

Copyright © 2019 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP.  See permissions for copyright questions and/or permission requests.